D.E. Shaw & Co
CTKB icon

D.E. Shaw & Co’s Cytek Biosciences CTKB Stock Holding History

D.E. Shaw & Co’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.14M Sell
260,125
-3,001
-1% -$14.2K ﹤0.01% 3356
2025
Q4 		$1.33M Buy
263,126
+142,104
+117% +$660K ﹤0.01% 3355
2025
Q3 		$420K Buy
+121,022
New +$454K ﹤0.01% 3947
2023
Q2 		– Sell
-133,249
Closed -$1.22M – 4287
2023
Q1 		$1.22M Sell
133,249
-56,430
-30% -$607K ﹤0.01% 3015
2022
Q4 		$1.94M Buy
189,679
+102,166
+117% +$1.37M ﹤0.01% 2972
2022
Q3 		$1.29M Sell
87,513
-123,289
-58% -$1.6M ﹤0.01% 3391
2022
Q2 		$2.26M Sell
210,802
-523,254
-71% -$5.21M ﹤0.01% 2958
2022
Q1 		$7.91M Buy
734,056
+718,217
+4,534% +$9.7M 0.01% 1824
2021
Q4 		$258K Buy
+15,839
New +$332K ﹤0.01% 4754

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co's CTKB Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Cytek Biosciences (CTKB) stake by 1.1% in Q1 2026, selling an estimated $14.2K and leaving 260,125 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3356.

D.E. Shaw & Co first reported a position in CTKB in Q4 2021 and has held it in 9 quarters since. The position peaked at $7.91M in Q1 2022. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • D.E. Shaw & Co held 260,125 shares of Cytek Biosciences worth $1.14M as of Q1 2026.
  • D.E. Shaw & Co sold 3,001 Cytek Biosciences shares in Q1 2026, an estimated $14.2K.
  • Cytek Biosciences made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3356 holding.
  • D.E. Shaw & Co first reported a position in Cytek Biosciences in Q4 2021 and has held it in 9 quarters since.
  • D.E. Shaw & Co's Cytek Biosciences position peaked at $7.91M in Q1 2022.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.